BioSite's Play for High-Value Diagnostics
Executive Summary
Biosite, a small point-of-care diagnostics company, has figured out a way to pay for access to genetic markers that could be the basis of important new diagnostics tests, without laying out big bucks. It is offering to provide genomics companies with antibodies developed using its proprietary methodology, which allows it to make high-affinity antibodies much faster than any other supplier. Partners, genomics or pharmaceutical companies, pay for the cost of the antibodies and give Biosite exclusive rights to any genetic markers they develop that may have diagnostic applications. Already Biosite has one alliance with Scios Inc., a genomics company working in the area of cardiovascular and kidney diseases.
You may also be interested in...
Can Ischemia Technologies Produce the Next Big Cardiac Marker?
In recent years, some creative diagnostic companies have applied pharmaceutical-like marketing techniques to launches of their flagship products. Five-year-old Ischemia Technologies' launch strategy for its cardiac marker, ischemia-modified albumin (IMA) is based on tenets gleaned from these companies' success stories. It is supporting its marker of cardiac ischemia with strong clinical and market development programs, aimed not just at the laboratory but also at clinicians. But the inherent complexities and nuances of the opportunity it addresses are challenging.
Biosite: Building a Solid Franchise
Biosite is one of a few diagnostic companies that has had to grapple with a literal run on its product--a point-of-care proprietary cardiovascular test that took off in the marketplace almost immediately after it was introduced in 2000. Now, it faces two challenges: the advent of competition from large in-vitro diagnostic companies and following up with a seond act as its explosive growth slows to more normal levels.
Biosite: Building a Solid Franchise
Biosite is one of a few diagnostic companies that has had to grapple with a literal run on its product--a point-of-care proprietary cardiovascular test that took off in the marketplace almost immediately after it was introduced in 2000. Now, it faces two challenges: the advent of competition from large in-vitro diagnostic companies and following up with a seond act as its explosive growth slows to more normal levels.